Oncology | Treatment Sequencing | US | 2017

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.

Treatment Sequencing 2017 covers six oncology indications with competitive treatment landscapes:

  • Renal cell carcinoma (US)
  • Malignant melanoma (US)
  • Non-small-cell lung cancer (US)
  • Breast cancer (US)
  • Prostate cancer (EU5)
  • Chronic myeloid leukemia (US)
Login to access report

launch Related Market Assessment Reports